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mirrored by overactivation of NOX enzymes in peripheral 
CD11b+ cells in later phases of both MS and EAE. This 
effect is antagonized by systemic intake of the NOX inhibi-
tor and anti-oxidant epigallocatechin-3-gallate. Together, 
this persistent hyper-activation of oxidative enzymes sug-
gests an “oxidative stress memory” both in the periphery 
and CNS compartments, in chronic neuroinflammation.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory neuro-
degenerative disease characterized by multifocal infiltration 
of immune cells in the central nervous system (CNS). The 
first onset of inflammatory symptoms is called clinically 
isolated syndrome (CIS), and 30–70 % of CIS patients 
develop definitive MS [34]. In most patients MS has a 
Abstract The functional dynamics and cellular sources of 
oxidative stress are central to understanding MS pathogene-
sis but remain elusive, due to the lack of appropriate detec-
tion methods. Here we employ NAD(P)H fluorescence life-
time imaging to detect functional NADPH oxidases (NOX 
enzymes) in vivo to identify inflammatory monocytes, acti-
vated microglia, and astrocytes expressing NOX1 as major 
cellular sources of oxidative stress in the central nerv-
ous system of mice affected by experimental autoimmune 
encephalomyelitis (EAE). This directly affects neuronal 
function in vivo, indicated by sustained elevated neuronal 
calcium. The systemic involvement of oxidative stress is 
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relapsing–remitting course (RRMS), which is convention-
ally considered to reflect mainly inflammatory processes. 
It can, however, subsequently evolve into a secondary 
progressive disease (SPMS), thought to reflect more of a 
degenerative process [27, 41], leading to lasting and irre-
versible neurological disability.
Reactive oxygen species (ROS) generated by invading 
and resident CNS macrophages have been implicated in 
mediating demyelination and axonal damage [13, 38, 55, 
58, 60]. The term reactive oxygen species (ROS) refers to 
both free radicals and related molecules. There is evidence 
pointing to excessive ROS production as a major mecha-
nism causing damage in MS, as oxidized DNA, lipids and 
proteins were reported in CNS lesions, cerebrospinal fluid 
and plasma of MS patients [17, 21, 31]. To prevent ROS-
caused damage, cells have potent anti-oxidative mecha-
nisms. However, defects in anti-oxidant mechanisms and 
excessive ROS production that overwhelms the endog-
enous anti-oxidant capacity lead to oxidative stress. The 
most abundant source of ROS leading to oxidative stress 
is the respiratory burst, which is mediated by the nicotina-
mide adenine dinucleotide phosphate (NADPH) oxidases 
[NOX1, NOX2 (phox), NOX3, NOX4, DUOX1, DUOX2] 
[5]. The NOX enzymes catalyze the oxidation of molecu-
lar oxygen to its highly reactive anion O2
–. Recently, sig-
nificant up-regulation of NOX2 as well as histological 
co-localization of cytosolic and membrane-bound NOX2 
subunits have been described in MS, at lesion sites [13, 59]. 
Additionally, subunits of NOX2 are up-regulated in active 
lesions in experimental autoimmune encephalomyelitis 
(EAE), an animal model of MS [45]. Furthermore, other 
members of the NADPH oxidase family, including NOX1 
and NOX4 have the capacity to cause oxidative stress in 
the CNS [11, 30, 36, 43, 49]. NOX1 subunits have been 
described in active lesions in MS tissue in microglia/mac-
rophages as well as in astrocytes [13], and inhibition of 
NOX enzymes [9] and knockout of isotype-specific as well 
as isotype-common NOX subunits (gp91 [29], p47 [57]) 
decreased EAE severity and incidence. This suggests that 
NOX enzymes in general are major contributors to oxida-
tive stress by catalyzing the production of ROS, thus lead-
ing to CNS tissue damage. However, up to now, neither 
the catalytic activity of NOX enzymes leading to oxidative 
stress nor their cellular sources could be tracked, in vivo in 
the CNS and in the periphery.
Given the increasingly recognized importance of oxi-
dative stress in MS pathogenesis, anti-oxidant drugs are 
emerging as new therapeutic approaches [15]. One poten-
tial candidate is epigallocatechin-3-gallate (EGCG), a poly-
phenol present in green tea. We and others have shown that 
EGCG ameliorates EAE [2, 19, 22, 33, 61], and clinical tri-
als testing the benefits of EGCG in MS patients are ongo-
ing (NCT00525668, NCT00799890 and NCT01417312). 
There is in vitro data pointing to the inhibition of ROS 
production through EGCG [63]. It is known that EGCG 
competes with NADPH but not with NADH in binding to 
NADH-/NADPH-dependent enzymes [46]. However, the 
therapeutic effects of EGCG in vivo have not yet been ana-
lyzed on a cellular level.
Developed two decades ago, fluorescence lifetime imag-
ing (FLIM) has proven to be a reliable, quantitative tool to 
probe cellular parameters [1, 12, 24, 25, 35, 53]. In particu-
lar, the possibility to quantify the endogenous fluorescence 
of NAD(P)H or of flavoproteins has made FLIM an espe-
cially versatile probe of metabolic function [26, 51, 52], 
as this marker-free approach allows for the acquisition of 
unaltered, real-time data. Despite its power as a quantitative 
technique, FLIM requires a high fluorescence signal and thus 
could not be applied to deep-tissue imaging until recently 
[4]—a limitation which is particularly relevant to intravital 
imaging of protected, hardly accessible organs like the CNS 
[44]. In our previous work, we demonstrated that, in the 
context of oxidative stress, the increase of fluorescence life-
time of NAD(P)H is specific for NADPH (and not NADH) 
binding to members of the NOX family, both in murine 
polymorphonuclear cells [37] and in plant cells (Nicotiana 
tabacum) (unpublished data). These results are supported 
by recent studies showing the same increase in NAD(P)H 
fluorescence lifetime, in a more general context [6]. When 
using NAD(P)H-FLIM, all NADH- and NADPH-dependent 
enzymes which participate in biochemical reactions within 
the cell are simultaneously detected (up to several hundred 
enzymes). Thus, the activation of NOX enzymes can be une-
quivocally detected only at sites where these enzymes pref-
erentially bind the present coenzymes. The catalytic activity 
corresponding to such a situation implies an excessive ROS 
production, and thus oxidative stress, rather than a low, e.g., 
immunomodulatory, ROS production.
In the present study, we observe a spatio-temporal cor-
relation between the catalysts of oxidative stress (activated 
NOX enzymes) and neuronal damage in the CNS of mice 
affected by EAE. Furthermore, we validate this technique 
in the CNS by identifying macrophages and activated 
microglia as major cellular sources of activated NOX 
enzymes, and thus of oxidative stress, in the brain stem 
of mice with EAE. Using this novel technique, we show 
for the first time that astrocytes are also major contributors 
in generating oxidative stress in the CNS during chronic 
EAE. Additionally, we offer insight into the systemic 
dimensions of both EAE and MS by quantifying the activ-
ity of NADPH oxidases in peripheral monocytes, from the 
first presentation of symptoms to the chronic phase of the 
disease. This marker-free approach allows the direct moni-
toring of the therapeutic mechanism of the anti-oxidative 
drug EGCG in humans at a cellular and even sub-cellular 
level.
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Methods and materials
Two‑photon laser‑scanning microscopy (TPLSM)
FLIM experiments were performed using a specialized 
two-photon laser-scanning microscope based on a com-
mercial scan head (TriMScope, LaVision BioTec, Biele-
feld, Germany) [20, 44]. The detection of the fluorescence 
signals was accomplished either with photomultiplier 
tubes in the ranges 460 ± 30, 525 ± 25, 593 ± 20 nm or 
with a 16-channel parallelized TCSPC detector (FLIM-
X16, LaVision BioTec, Bielefeld, Germany) in the range 
460 ± 30 nm. The excitation of NADH and NADPH 
was performed at 760 nm (detection at 460 ± 30 nm), of 
Cerulean (detection at 460 ± 30 nm), sulforhodamine 
101 (detection at 593 ± 20 nm) and EGFP (detection at 
525 ± 25 nm) at 850 nm and of tdRFP either at 930 nm 
or at 1110 nm (detection at 593 ± 20 nm). Citrine was 
detected at 525 ± 25 and 593 ± 20 nm.
For both intensity and fluorescence lifetime imaging we 
used an average maximum laser power of 8 mW to avoid 
photodamage. The experimental parameters for FLIM were 
160 ps histogram bin (for NAD(P)H-FLIM) and 80 ps his-
togram bin (for FRET-FLIM) and maximum acquisition 
time for a 512 × 512 image was 5 s to record a fluorescence 
decay stack (Suppl. Fig. 3). The time window in which the 
fluorescence decays were acquired was set to 9 ns.
Data analysis
FLIM data analysis was performed using self-written soft-
ware based on Levenberg–Marquardt algorithms for non-
linear fitting as well as the phasor approach (Suppl. Fig. 6).
Statistical analysis and graphical presentation was car-
ried out with GraphPad Prism 4 (Graphpad Software, USA) 
and OriginPro (OriginLab, USA). Results are shown as 
mean values from analyzed data in one mouse/human, in 
addition the mean ± SD summarize collective data from 
performed experiments.
Mice
All mice used were on a C57/Bl6 background. The CerTN 
L15 x LysM tdRFP mouse expresses a FRET-based cal-
cium biosensor consisting of Cerulean (donor) and Citrine 
(acceptor) bound to troponin C, a calcium-sensitive protein 
present in certain subsets of neurons [18]. Mice carrying 
the CerTN L15 reporter were crossed to the LysM tdRFP 
mice, in which tdRFP [32] is expressed in LysM+ cells 
[10], yielding progeny with both reporters. The CX3CR1
+/− 
EGFP mouse [23] was used to detect microglia, whereas 
the CD4+ YFP mouse strain was used to detect CD4+ T 
cells [28, 50]. EAE induction protocol and EAE course of 
these mice can be found in Table 2, Supplemental Material.
Preparation of the brain stem window for intravital 
imaging
The preparation of the imaging field was similar to our pre-
vious description [47, 48]. For a detailed description, see 
Supplemental Material. In each imaged animal the whole 
area that was accessible by intravital imaging was scanned 
and all visible lesions of each animal were analyzed as well 
as at least one “normal appearing” imaging field. Animal 
experiments were approved by the appropriate state com-
mittees for animal welfare (G0198/11 and G0181/10, 
LAGeSo—Landesamt für Gesundheit und Soziales Berlin) 
and were performed in accordance with current guidelines 
and regulations.
Human samples
Venous blood samples were obtained with informed con-
sent after the nature and possible consequences of the stud-
ies were explained. We included healthy controls, patients 
with untreated clinically isolated syndrome (CIS), patients 
with relapsing remitting MS (RRMS-GA) in a randomized 
double-blind clinical trial medicated with glatiramer ace-
tate receiving additional 600 mg of EGCG or placebo, 
patients with relapse and remitting MS not treated with 
any immunomodulatory drugs (RRMS), and patients with 
a secondary progressive disease course (SPMS); further 
detailed information can be found in Table I, Supplemen-
tal Material. Peripheral blood mononuclear cells (PBMCs) 
were isolated using standard protocols and CD11b+-
enriched by MACS selection (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to the manufacturer’s 
protocol. The purity was assessed by flow cytometry. The 
MACS-enriched CD11b+ monocytes were injected into 
specifically fabricated chambers and incubated in phenol-
free RPMI at 37° C for one hour prior to imaging.
Further experimental details are available in Supplemen-
tal Methods.
Results
Activation of NOX enzymes measured by intravital 
NAD(P)H fluorescence lifetime imaging pinpoints the 
origin of oxidative stress and correlates with immune 
infiltration and neuronal dysfunction in EAE
To detect and quantify NOX enzymes activation in vivo, 
we induced EAE in mice and imaged their brainstem 
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intravitally. Consistent with previous reports [38], we 
detected elevated ROS concentrations (~200 µM) in the 
brain stem of mice affected by EAE at the peak of disease, 
compared to disease-free control animals (Fig. 1a). ROS 
were detected by intravital imaging of murine brainstems 
which had been previously superfused with a 100 µM solu-
tion of Amplex Red®. The Amplex Red® calibration was 
performed using a H2O2 concentration series (Suppl. Fig. 2).
As the main catalysts of O2
− production (precursor of 
ROS) the membrane-bound NOX enzymes (NOX1,2,3,4 
and DUOX1,2) directly contribute to oxidative stress. By 
employing intravital NAD(P)H fluorescence lifetime imag-
ing (FLIM) we detected the activation of NOX enzymes 
in the brainstem of EAE mice (Table 2). From the fluores-
cence intensity decay of NAD(P)H, we evaluated the fluo-
rescence lifetime of enzyme-bound NAD(P)H at each pixel 
of the image in different layers of the brainstem between 
30 and 150 µm depth, as described in Supplemental Mate-
rial. We expected a mean fluorescence lifetime between 
1.1 and 2.7 ns for NAD(P)H bound to metabolic enzymes 
responsible for basic cellular functions (Suppl. Fig. 4) 
and a fluorescence lifetime of approximately 3.65 ns for 
NADPH bound to NOX enzymes as calculated with two 
independent evaluation methods [37] (Supplemental Mate-
rial, Suppl. Figs. 4 and 6). Free NAD(P)H has a fluores-
cence lifetime of approx. 400 ps and is easily distinguished 
from enzyme-bound NAD(P)H.
The specific NAD(P)H fluorescence lifetime (“NOX 
only” gate set at 3.3–3.9 ns) corresponding to activated 
NOX enzymes was detectable in EAE mice mainly 
within those brainstem regions that included immune cell 
infiltrations (LysM+tdRFP or CD4+YFP cells, Movie 
1); that is, NOX enzymes overactivation was detected 
in acute lesions, but could not be detected in “normal 
appearing” areas in the same animal (peak disease, score 
2.5, Fig. 1b, c).
The area of NOX-specific activation in acute lesions in 
the brainstem was significantly enlarged, both at the onset 
of clinical signs, with a mean of 5 ± 1.5 % in the field of 
view (300 × 300 µm2), and at the peak of disease, with a 
mean area of 14.9 ± 5.8 %, as compared to healthy ani-
mals, with a mean area of 2.2 ± 0.9 % (Fig. 1e).
By performing intravital FRET-FLIM in the brain stem 
of CerTNL15xLysMtdRFP mice with EAE, we were able to 
confirm and extend our previous results indicating neuronal 
dysfunction during the disease (Fig. 1d, f). We showed 
previously that elevated Ca2+ concentrations over 1 µM in 
these mice over a period of 1 h reliably indicate neuronal 
dysfunction [48]. Here, we confirm this finding by show-
ing that neuronal and axonal calcium is increased in areas 
adjacent to immune infiltrates. Additionally, after 2 h of 
intravital monitoring, the sites of increased axonal calcium 
showed axonal disintegration (Fig. 1h). Both the TN L15 
construct decay time and the acquisition time of the FRET-
FLIM technique are in the range of several 100 ms, allow-
ing for recording time-averaged calcium concentrations 
relevant for the pathologic dysfunction of neurons. They 
are, however, both too slow to monitor neuronal calcium 
transients.
By simultaneously performing NAD(P)H-FLIM 
and FRET-FLIM in the brainstems of mice with EAE, 
Fig. 1  Activation of NADPH oxidases in the CNS pinpoints oxida-
tive stress. Oxidative stress is dependent on disease severity and cor-
relates with cellular inflammation and neuronal dysfunction. ROS 
concentration in the brain stem of a healthy mouse compared to a 
mouse affected by EAE at peak of disease (score 2.0) (a). Amplex 
Red® was used as ROS indicator. λexc = 910 nm, λem = 525 ± 25 nm 
(Thy1-Citrine in neurons depicted in green), λem = 593 ± 20 nm 
(Amplex Red®), scale bar 50 µm. b Correlated 300 × 300 µm2 
(517 × 517 pixel) fluorescence intensity images [Thy1 = green 
(neurons), LysM = red (macrophages)], c enzyme-bound 
NAD(P)H-FLIM maps (τ2-maps) and d neuronal Ca
2+ maps as 
recorded by FRET-FLIM in three different regions of the brain stem 
of a CerTN L15 x LysM tdRFP mouse with EAE, at the peak of the 
disease, score = 2.5. First row normal appearing white matter; sec-
ond row margin of lesion; third row lesion center. The activation of 
the NADPH oxidases (NOX) assessed by NAD(P)H-FLIM (c) cor-
relates with LysM+ tdRFP cell infiltrate in the CNS (b) and with 
elevated neuronal calcium (d), indicating neuronal dysfunction. 
Scale bars in b, c and d = 30 µm. The τ2-maps show the false color-
encoded fluorescence lifetime τ of enzyme-bound NAD(P)H at each 
recorded pixel of the image. NAD(P)H bound to metabolic enzymes 
are depicted in blue and green (τ between 1 and 3 ns) whereas, under 
oxidative stress, NADPH bound to activated NOX appears in red (τ 
between 3.3 and 3.9 ns, “NOX only” gate). e Quantification of the 
NOX activation area within lesions defined by LysM+ cell infiltra-
tion, i.e., ratio of the area of NOX only gate to the total tissue area, 
4.98 ± 1.53 % at the onset of clinical signs (day 1–2 after appearance 
of first clinical signs, EAE scores 0.5–1.0) and 14.88 ± 5.81 % of the 
tissue area at peak of disease (day 3–5 after onset of clinical symp-
toms, EAE scores 1.5–2.5) as compared to 2.19 ± 0.94 % in healthy 
controls. Six independent EAE experiments (EAE onset n = 6, EAE 
peak n = 12 healthy controls n = 3), see Table 2. f Quantification of 
elevated neuronal calcium area is assessed by FRET-FLIM relative to 
the total neuronal area. Data display means of imaging fields of indi-
vidual animals from two independent EAE experiments (healthy con-
trols n = 3, EAE onset n = 3, EAE peak n = 4). The increased NOX 
activity correlates with an increased area of elevated neuronal calcium 
(“Ca2+ > 1 µM” gate) at the time of EAE onset (1.32 ± 0.78 %) and 
at peak disease (12.80 ± 2.41 %), as compared to healthy controls 
(0 %, n = 3, mean calcium concentration 170 nM, maximum calcium 
concentration 450 nM). g Correlation between NOX enzymes activa-
tion area and increased neuronal calcium area at lesion sites and non-
infiltrated sites in the brain stem of CerTN L15 x LysM tdRFP mice 
affected by EAE. h Pathologically increased neuronal calcium level 
(>1 µM calcium) correlates with immune cell infiltrate and, after 2 h, 
with axonal break-down as shown by intravital images in the brain 
stem of a CerTN L15 mouse affected by EAE (peak)—scale bar 
10 µm. All images are acquired in the region 30–150 µm depth within 
the brain stem (300 × 300 × 50 µm3, z-step = 2 µm). For the statistic 
evaluation in e and f we applied ANOVA tests (*p < 0.05, **p < 0.01, 
***p < 0.001)
▸
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we found that the increased NOX activation correlated 
with an extended area of elevated neuronal calcium 
(“Ca2+ >1 µM” gate) at EAE onset (1.3 ± 0.8 %) and 
at peak disease (12.8 ± 2.4 %), as compared to con-
trol mice (0 %) (Fig. 1g). The high spatial correlation 
between areas of NOX enzymes activation and increased 
neuronal calcium indicating early neuronal dysfunction 
(Pearson’s R coefficient over 0.9) in EAE is depicted in 
Fig. 1g. Interestingly, at lesion sites, both the overactiva-
tion of NOX enzymes and the neuronal dysfunction were 
generally lower at onset than at disease peak. The areas 
of NOX enzymes activation and increased calcium values 
were determined as mean values of 3–12 acute lesions per 
mouse. Each data point in Fig. 1e, f represents the average 
value for each individual mouse.
Cellular origins of oxidative stress in EAE
We verified the capacity of intravital NAD(P)H-FLIM to 
identify the cellular origins of oxidative stress directly in 
the CNS by confirming the contributions of macrophages 
and activated microglia, which are well-known contribu-
tors to the activation of NOX enzymes during EAE. Sub-
sequently, we used the unique versatility of this technique 
to identify novel cellular sources of oxidative stress by 
performing endogenous NAD(P)H-FLIM in the CNS 
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of EAE mice with a variety of fluorescently labeled cell 
subsets. Here, we evaluated the relative contributions 
of each cell type (LysM+tdRFP, CerTNL15, CD4+YFP, 
CX3CR1
+/−EGFP or sulforhodamine101 labeled cells) to 
the total area of NOX enzymes activity.
Characterization of cellular markers
The reliability of the chosen cellular markers used in the intra-
vital experiments was verified by flow cytometry or histology 
in mice affected by EAE. While in healthy LysM+tdRFP 
animals only rare tdRFP+ cells can be found in the CNS, 
during EAE (n = 4) the tdRFP+ compartment increased 
markedly at lesion sites. Of the tdRFP+ cells, 65 % were 
CD45highCD11b+Ly6G− (macrophages), 25 % CD45low-
CD11b+ (microglia) and 7 % CD45highCD11b+Ly6G+ (neu-
trophil granulocytes) (Fig. 2a). The overlap of LysM+tdRFP 
cells with CX3CR1
+ cells was quantified by flow cytom-
etry using an anti-CX3CR1 antibody. 17.8 ± 8.9 % of all 
LysMtdRFP+ cells were CX3CR1
+CD45low (microglia) and 
27.6 ± 10.1 % were CX3CR1+CD45high (macrophages). This 
represented only a minority of the total CX3CR1
+ cells as dis-
played in the 2.8 ± 1.4 % of cells that co-expressed LysM- 
tdRFP (n = 3) (Fig. 2b).
In disease-free control animals, sulforhodamine 101 
(sulforh101) specifically labels astrocytes in the cortex [39, 
40]. To characterize the cells labeled with sulforh101 dur-
ing EAE in the brainstem we analyzed by immunofluores-
cence intracellular sulforh101 (following i.v. injection) as 
well as GFAP and CD11b expression. Minimal co-locali-
zation (6.1 ± 1.4 %) of sulforh101 labeling with CD11b 
staining could be observed at EAE lesion sites in the brain-
stem (Fig. 2c). We detected sulforh101 co-localization 
mainly with GFAPlow cells [16] but not with GFAPhigh 
cells (Fig. 2d). 80 ± 6 % of sulforh101-labeled cells were 
GFAP+, whereas this cell population represents only half of 
all GFAP-expressing cells (Fig. 2d). Intravital imaging data 
recorded in the brainstem of CX3CR1
+/−EGFP mice addi-
tionally labeled with sulforh101 showed negligible over-
lap between the EGFP and sulforh101 labeling, typically 
2 ± 1.5 %, both in healthy controls and in mice affected by 
EAE (Fig. 3a). The lesions investigated by intravital imag-
ing in the brainstem showed typical EAE characteristics, 
which we confirmed by histology (Suppl. Fig. 1).
Phagocytic capacity of astrocytes and their potential 
role in EAE
We focused on astrocytes as potential contributors to oxi-
dative stress during neuroinflammation as they are known 
to have phagocytic capacity. Morphological analysis of 
our intravital experiments revealed a disruption of the fine 
process-rich astrocytic network typically found in healthy 
control animals (Fig. 3a), similar to that which could be 
seen on histological staining (Fig. 2). The disruption of the 
astrocytic network was associated with changes towards a 
reactive phenotype and glial scar formation at lesion sites, 
with dense accumulations of astrocytic end feet and pro-
cesses lining up along the vessels and around inflammatory 
cells (CX3CR1
+) in EAE (Figs. 2d, 3a).
Furthermore, NAD(P)H-FLIM analysis in astrocytes 
using beads for phagocytosis coated with Staphylococcus 
aureus fragments (pHrodo) in mixed cell cultures with 
microglia showed increased NAD(P)H fluorescence life-
time typical of NOX enzymes activity. We could correlate 
increased NOX enzymes activation with the localization of 
phagocytosed pHrodo beads (red) (Fig. 3b).
As the expression of p22 NOX subunit in astrocytes 
during EAE is only sparse [45], we investigated Noxo1 
expression by immunofluorescence to address the question 
which NOX enzyme could be responsible for the observed 
NAD(P)H lifetime prolongation. NOX1 function is less 
dependent on p22 coexpression compared to other isoforms 
[54]. We could detect in GFAPhigh cells and GFAPlow cells 
Noxo1 expression (Fig. 3c, d) including GFAPlow and sul-
forh101-co-labeled cells (Fig. 3g) in EAE lesions. Further-
more, Noxo1 was also found in CD11b+ cells (with both 
phagocytic and microglial morphology) (Fig. 3e).
Altogether, these data suggest that astrocytes gener-
ate oxidative stress within the CNS during the course of 
chronic neuroinflammation.
Astrocytes are major cellular contributors to oxidative 
stress in EAE
We quantified the contribution of specific cell types to the 
total area of NOX enzymes activity in the CNS using the 
cellular markers described above. In line with previous 
studies, we found that the mean contribution of LysM+ 
cells amounted to 22.7 ± 6.4 % at onset, and 28.2 ± 4.7 % 
at the peak of EAE. Additionally, the mean contribution 
of CX3CR1
+cells amounted to 13.1 ± 2.3 % at onset, and 
17.4 ± 2.4 % at the peak of EAE. Macrophages and micro-
glia (either LysM+ and/or CX3CR1
+) together constitute 
the main source of oxidative stress at onset and peak of 
the disease (Fig. 4d). This finding confirms the reliability 
of our method to evaluate oxidative stress by detecting the 
activation of NOX enzymes.
Using this novel approach, we found that although 
microglia and macrophages are the main sources of NOX 
enzymes activity, a significant fraction could not be attrib-
uted to those cell types. Surprisingly, we found that astro-
cytes (sulforhodamine 101-labeled cells [3]) accounted for 
26.4 ± 4.4 and 34.2 ± 5.6 % of total area of NOX enzymes 
overactivation at onset and peak of EAE, respectively 
(Fig. 4d). In this model, the contribution of astrocytes to 
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oxidative stress within the CNS is comparable to that of 
the labeled macrophages and microglia together, thus iden-
tifying astrocytes also as central contributors to oxidative 
stress in the acute phases of EAE.
The mean contribution of CD4+cells to NOX enzymes 
activity was negligible, amounting to 3.6 % at peak disease, 
comparable to the mean contribution of neurons with 2.3 % 
at onset and 3.8 % at peak of EAE (Fig. 4d).
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Fig. 2  Characterization of active lesions as well as of LysMtdRFP+ 
and sulforhodamine 101 labeled cells during EAE. a FACS analysis 
data in the CNS of LysM+tdRFP mice at peak EAE, characterizing 
the tdRFP+ cell population (n = 4). b FACS analysis data in the CNS 
of LysM+tdRFP mice (n = 3) at peak EAE showing the overlap of 
LysMtdRFP and CX3CR1-antibody labeled cells. c Immunofluores-
cence images within the brain stem of a C57Bl6 mouse affected by 
EAE, at peak of the disease, showing no co-localisation between sul-
forhodamine 101 (red) and CD11b+ cells (green) at infiltration sites. 
d Immunofluorescence images within the brain stem of the same 
mouse, showing colocalization between sulforhodamine 101 (red) 
and GFAP+ cells (green) at reactive gliosis sites. Scale bar 200 µm
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We further analyzed the fraction of activation within 
each cell subset by calculating the percentage of the spe-
cific cell area that shows NOX enzymes activation, as well 
as averaged values per mouse displayed in Fig. 4e. The area 
of NOX enzymes activation within neurons (Thy1+ cells 
in LysM+tdRFPxCerTNL15 mice) was very small, both at 
clinical onset and at peak of disease with less than 2 %. 
Conversely, in LysM+tdRFP cells the area of NOX enzymes 
activation was generally higher with 8 % at clinical onset 
and rising significantly to 27 % at peak disease (Fig. 4e). 
The area of NOX enzymes activation in CX3CR1
+/−EGFP 
cells was 11 and 14 %, respectively. We obtained similar 
data in astrocytes with 12 % at onset and 10 % in peak. In 
CD4+YFP cells, the area of NOX enzymes activation was 
low at peak of disease, amounting to only 3 %.
In our experimental setup, not all cells of the specific 
cell subtype are fluorescently labeled also due to the use 
of heterozygous fluorescent mouse strains, but we could 
address the majority of cells with our labeling strategy. 
The remaining percentage of NOX enzyme activation area 
that was not associated with labeled cells in this model 
(12.85 % at peak, 35.46 % in onset of EAE) is probably 
due to unlabeled macrophages, microglia and/or astro-
cytes. The contribution of other immune or CNS-specific 
cell types, such as oligodendrocytes or immune cells with 
phagocytic capacity, to the generation of oxidative stress 
cannot be completely excluded but is expected to be low.
Soluble factors drive activation of NADPH oxidases 
in EAE
Regarding the co-localization of neuronal structures 
(Thy1+ cells) and LysM+ cells in CerTNL15xLysMtdRFP 
mice, we found that only a 28 to 30 % of the co-localized 
area was associated with increased NOX enzymes activa-
tion in EAE (Fig. 4f, h). The normalized co-localization 
index, calculated as we previously described [48] indicated 
significantly more extensive interaction between neurons 
and macrophages at peak disease than at the time of onset 
(Fig. 4g), independently of the number of neurons or mac-
rophages at the imaged site. Thus, while the interactions 
between neurons and LysM+ cells were more extensive 
with the progression of the disease, NOX enzymes activa-
tion was not specifically induced by neurons or by their 
direct interaction with LysM+ cells. On the other hand, we 
showed that upon applying glutamate (300 µM) locally to 
the brainstem of healthy mice, the NOX enzymes activa-
tion area increased from values typical for control animals 
(0.7 ± 0.2 %) to values similar as those reached in peak 
of EAE (11.9 ± 3.1 %) (Suppl. Fig. 5), indicating that 
glutamate-induced excitotoxicity can lead to similar levels 
of NOX enzymes activation as are present in acute EAE 
lesions. These data support the interpretation that the cause 
of NOX enzymes activity in macrophages, activated micro-
glia and astrocytes within the CNS in EAE is not neces-
sarily triggered by direct contact to CNS components like 
axons, but is rather associated with soluble factors, such as 
glutamate or inflammatory mediators.
NOX is overactivated in peripheral CD11b+ monocytes 
in both MS and EAE and can be ameliorated 
by systemic administration of EGCG
To translate our findings to MS, we isolated CD11b+ 
monocytes from peripheral blood mononuclear cells 
(PBMC) taken from MS patients, at different stages of 
the disease, including CIS, RRMS and SPMS. In healthy 
humans and healthy mice, CD11b+ monocytes were not 
activated after isolation, i.e., the area of NOX activation 
amounted to 3.4 ± 0.6 and 3.4 ± 1.9 %, respectively. In 
untreated RRMS patients, the area of NOX activation was 
18.3 ± 2.5 %, in mice at peak of EAE, the NOX activa-
tion area was 18.5 ± 3.5 %. The high levels of NOX acti-
vation in peripheral CD11b+ cells of mice with EAE and 
of untreated RRMS patients could be ameliorated by 
treatment with glatiramer acetate (GA) alone, to only 
10.8 ± 2.8 % (in RRMS patients). Upon combination treat-
ment with both GA and additional systemic administration 
Fig. 3  Astrocytes as phagocytes and their potential role in EAE. a 
3D fluorescence intensity images were acquired in the brain stem of 
CD4+ YFP mice: healthy controls (upper, left panel) and at a lesion 
site, in EAE (upper, right panel) [CD4+ cells (YFP) = green, astro-
cytes (sulforhodamine 101) = red]. Scale bar 100 µm. Similarly, 
3D fluorescence intensity images were acquired in the brain stem of 
CX3CR1
+/− EGFP mice: healthy controls (lower, left panel) and at 
the lesion site in EAE (lower, right panel) [microglia/macrophages 
(EGFP) = green, astrocytes (sulforhodamine 101) = red]. Scale bar 
30 µm. b NAD(P)H fluorescence images (blue) of mixed astrocytes 
(arrow head) and microglia (arrows) cell cultures phagocytosing 
Staphylococcus aureus beads (pHrodo, red after uptake) are shown 
on the right side. Corresponding NAD(P)H-FLIM maps (τ2-maps) 
shown on the left side reveal the correlation between phagocytosis 
of pHrodo beads and the typical increase of fluorescence lifetime in 
astrocytes indicating the activation of NOX enzymes. c Immunofluo-
rescence overview image within the brain stem of a mouse affected 
by EAE indicating the distribution of Noxo1 (subunit of NOX1, red) 
and GFAP signal (green). Scale bar 100 µm. d Zoom ins of c dem-
onstrating that Noxo1 is found both in GFAPhigh cells (indicated by 
white arrows) and GFAPlow cells (indicated by white arrow heads) in 
the CNS of mice affected by EAE. Scale bar 30 µm. e Immunofluo-
rescence overview image within the brain stem of a mouse affected 
by EAE indicating the distribution of Noxo1 (subunit of NOX1, red) 
and CD11b signal (green). Scale bar 150 µm. f Zoom ins of e demon-
strating that Noxo1 is found in CD11b+ cells (with both phagocytic 
and microglial morphology). Scale bar 40 µm (upper panels), scale 
bar 20 µm (lower panels). g Immunofluorescence overview image 
within the brain stem of a mouse affected by EAE indicating the dis-
tribution of Noxo1 (subunit of NOX1, gray), GFAP signal (green) 
and sulforh101 signal (red). Scale bar 200 µm. h Zoom in of g dem-
onstrating that Noxo1 is found in GFAPlow, sulforh101-labeled cells. 
Scale bar 30 µm
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of EGCG, levels were even further reduced, almost to 
the levels of healthy controls: 5.8 ± 3.4 % in mice and 
6.4 ± 1.2 % in RRMS patients (Fig. 5).
To understand the kinetics of NOX activation leading 
to oxidative stress during the course of the disease, we 
analyzed PBMCs of newly diagnosed (untreated) patients 
with CIS, untreated RRMS patients and differently treated 
SPMS patients. We observed little NOX activation in CIS 
patients (3.6 ± 1.2 %), and markedly elevated NOX acti-
vation in untreated RRMS patients (18.3 ± 2.5 %) and 
in treated SPMS patients (15.1 ± 3.2 %) (Fig. 5b). These 
data could be reproduced in mice, since at onset of dis-
ease CD11b+ splenocytes showed almost normal NOX 
activation (5.0 ± 1.1 % %), while at peak of disease the 
values were similar to those measured in untreated RRMS 
patients (18.5 ± 3.5 %). Immunization with adjuvant only 
(CFA without MOG) did not increase NOX activation 
(3.0 ± 0.9 %) in CD11b+ splenocytes. All values of NOX 
activation area represent mean values acquired over 30–120 
cells per individual.
To address if EGCG counteracts a possible overexpres-
sion of NOX2 subunits in MS, rather than direct NOX2 
overactivation, we performed qRT-PCR analysis of PBMCs 
from ECGC-treated and untreated patients. We did not 
detect any differences in the expression level of the gp91 
(NOX2 subunit) in patients treated with GA and placebo 
as compared to treatment with GA and EGCG (Fig. 6e), 
indicating that the reduced activation of NOX2 in EGCG-
treated patients was not caused by reduced gp91 gene 
expression. Rather, this observation could be explained 
by direct inhibition of NOX2 activation by EGCG, which 
is in accordance with the fact that EGCG competes with 
NADPH in binding to the NADPH-binding site of enzymes 
[6] including the NADPH oxidases (NOX enzymes). In 
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vitro data from our group using 100 µM EGCG yielded 
similar results, as they lead to an immediate shift with more 
free NAD(P)H with a shorter fluorescence lifetime (data 
not shown).
As NOX2 activity requires the fusion of the membrane-
bound p22 and cytosolic p47 components, we examined the 
co-localization of p22 and p47 in human CD11b+ PBMCs 
by imaging cytometry to confirm our FLIM data with an 
independent approach. The co-localization was quantified 
as the Bright Detail Similarity (BDS), which measures the 
correlation coefficient between the intensities in localized 
bright spots of radius 1 µm or less. In healthy donors, less 
than 0.1 % of CD11b+ cells demonstrated co-localization of 
the p22 and p47 subunits, as indicated by a BDS >2, while 
RRMS patients had a markedly increased proportion of 
cells in which the two subunits co-localized, with 3.6 % of 
CD11b+ cells having a BDS >2 (Fig. 6a–c). Using a DCF 
(Di-Chloridium Fluorescein) fluorescence-based ROS/
RNS detection assay in serum, we measured a general trend 
towards lower ROS/RNS concentrations in GA-treated 
RRMS patients with EGCG co-therapy as compared to pla-
cebo (Fig. 6d). Consistent with MS pathology (with the brain 
as the target of inflammation) and the frequencies of overac-
tivated cells in the blood as detected with imaging cytometry, 
the ROS/RNS are highly diluted in serum, and were not sig-
nificantly different between the groups under investigation.
Discussion
To elucidate how oxidative stress causes neuronal degen-
eration and to clarify the mechanisms of anti-oxidant ther-
apy, it is necessary to have a tool which allows real-time 
monitoring of functional changes at cellular and sub-cellu-
lar level. Applying this tool both within the central nervous 
system—where the damage takes place—and in the periph-
eral immune system demonstrates novel links between 
human disease and animal models, and offers unique func-
tional insights into the systemic impact of MS.
In the present study, we monitored for the first time the 
functionality of NADPH oxidases catalyzing the production 
of ROS, which leads to oxidative stress in vivo. The fact that 
NOX enzymes are membrane-bound enzymes facilitates the 
identification of their cellular origins. Our intravital imag-
ing and marker-free NAD(P)H-FLIM data demonstrate 
that NADPH oxidases are overactivated in astrocytes (sul-
forh101 labeled) during neuroinflammation, in addition to 
the known contributors, LysM+ and CX3CR1
+ phagocytes, 
previously reported and recently corroborated in bone mar-
row chimeric mice deficient for NRROS, a negative regula-
tor of ROS [38, 42]. Our intravital data regarding the role 
of astrocytes in chronic neuroinflammation are supported 
by histological studies showing that Noxo1 is expressed in 
GFAP+ cells, and that negative p22 immunostaining [45] in 
astrocytes does not exclude a NOX2-independent functional 
NADPH oxidases activation in vivo [54]. Additionally, we 
showed that NOX enzymes activation was spatially associ-
ated with lesion sites in EAE, and correlated with locations 
of neuronal dysfunction. This finding is consistent with the 
report that mice with knockout of the common subunit of 
NOX enzymes (p47−/− mice) are more resistant to EAE 
[57] supporting the idea that NOX2, the phagocytic isotype, 
is not the only member of the NOX family that may contrib-
ute to excessive ROS production in chronic neuroinflamma-
tion. In line with this, mice lacking only NOX2 (gp91−/−) 
develop only a slightly milder form of EAE [29] and expres-
sion levels of NOX enzyme subunits other than NOX2 
Fig. 4  Cellular origin of NADPH oxidases activity in the CNS of 
EAE mice. a The fluorescence intensity image and the τ2 NAD(P)
H-FLIM map of whole tissue area was used to analyze the cellular 
origin of NOX activation signal in the CNS. Therefore, we performed 
an overlay of both images and analyzed the NAD(P)H-FLIM signal 
at the areas of the respective cell types. Exemplarily LysM+ cells as 
well as Thy1+ cells (neurons) in (a), CX3CR1
+/− EGFP—green or sul-
forhodamine 101—red (astrocytes) in b and CD4+ YFP—green (T 
cells) or sulforhodamine 101—red (astrocytes) in c are shown in the 
brain stem of mice affected by EAE. All τ2 NAD(P)H-FLIM images 
depict the normalized area of NOX activation in relation to the total 
cellular area in the respective cell subsets. Scale bar 30 µm (a) and 
50 µm (b, c). Quantification of the contribution of LysM, Thy1, 
CX3XR1, CD4
+ and sulforhodamine 101-labeled cell subsets, respec-
tively, to the total area of NOX enzymes activation within a lesion. 
LysM+ phagocytes: 22.7 % at onset and 28.2 % at the peak of EAE, 
CX3CR1
+ cells: 13.1 % at onset and 17.4 % at the peak of EAE, 
astrocytes (sulforhodamine 101): is 26.2 and 37.0 %, CD4+ cells: 
3.6 % at peak disease, neurons (Thy1+): 2.3 % at onset and 3.8 % at 
peak (d). To analyze the proportion of activated cells in one specific 
cell subset, we quantified the NOX enzymes activation area relative 
to the total area of the respective cell type at onset and peak of dis-
ease (e). The area of NOX activation within neurons (Thy1+ cells in 
the LysM+tdRFP x CerTN L15 mice): onset 0.8 ± 0.5 % and peak 
1.8 ± 0.4 %, LysM+ cells onset 7.9 ± 2.3 %, and peak 26.4 ± 6.6 %, 
CX3CR1
+ cells: onset 10.6 ± 0.6 % and peak 14.4 ± 1.7 %, 
astrocytes (sulforhodamine 101): onset 11.7 ± 0.6 % and peak 
9.8 ± 1.6 %, CD4+ cells: peak 3.1 ± 2.0 %. Data from 2 EAE experi-
ments in LysM+tdRFP x CerTN L15 mice, n = 3 onset, peak n = 4; 2 
EAE experiments in CX3XR1
+/− EGFP mice labeled with sulforhoda-
mine 101, n = 2 onset and n = 3 peak; 1 EAE experiment in CD4+ 
YFP mice labeled with sulforhodamine 101, peak n = 2 (e). Left fluo-
rescence intensity image of brain stem lesion in EAE (Thy1 = green, 
LysM = red, colocalisation = white). τ2 (enzyme-bound) NAD(P)
H-FLIM image of LysM+tdRFP cells in tissue (middle) and at the 
Thy1/LysM colocalisation area (right) depicts the normalized area of 
NOX enzymes activation in relation to total LysM+ cellular area as 
well as the activation within the colocalisation area. Scale bar 30 µm 
(f). The normalized colocalisation index indicates the interaction level 
between LysM+ and Thy1 cells, respectively, in onset and in peak of 
the disease, in the same experiments (g). Quantification of the mean 
NOX activation area of individual mice relative to the total area of 
LysM/Thy1 colocalisation at the onset (n = 3) and peak (n = 4) of 
disease, two independent EAE experiments (h). All images are 
acquired in 30–150 µm depth within the brain stem (z-step = 2 µm). 
For statistic evaluation in d we applied the ANOVA test, in g and h 
Mann–Whitney U tests (*p < 0.05, **p < 0.01, ***p < 0.001)
◂
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were elevated within active MS lesions [13]. One addi-
tional candidate is NOX1, which was reported to be neu-
rotoxic in microglia [8]. Importantly, our NAD(P)H-FLIM 
technique to detect the catalysis of oxidative stress does 
not discriminate between NOX isotypes. Rather, it detects 
their increased activation as compared to other NAD(P)H- 
dependent enzymes responsible for basic cellular pro-
cesses that are present in the same observation volume 
(0.4 × 0.4 × 1.5 µm3). Therefore, the hallmark of our tech-
nique is its capacity to monitor excessive NOX enzyme 
function as a reliable indicator of oxidative stress, rather 
than dissecting the activation of specific NOX isotypes.
NADPH oxidases activation was not restricted to 
a specific cell type, and was not preferentially found 
co-localized with the major compartments of the immune 
system (macrophages/activated microglia) and of the CNS 
(neurons), suggesting a predominant contribution of locally 
acting soluble factors like TNF-α or glutamate [15, 62]. 
Glutamate is not only an excitotoxic factor but was also 
shown to induce NOX activation. Supporting this interpre-
tation, we found that local treatment with glutamate caused 
a significant increase of the NOX enzymes activation area 
as revealed by intravital NAD(P)H-FLIM in the brain stem 
of healthy mice (Suppl. Fig. 5).
As macrophages/microglia are two of the main produc-
ers of ROS in EAE, it was unexpected that only up to 50 % 
of the area of macrophages/microglia (LysM+tdRFP cells 
and CX3CR1
+/−EGFP cells) showed activation of NOX 
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Fig. 5  NOX activation in murine and human peripheral CD11b+ 
cells during chronic neuroinflammation as compared to treatment 
with EGCG. a Quantification of mean normalized area of NOX acti-
vation as measured from τ2 (enzyme-bound) NAD(P)H fluorescence 
lifetime images of MACS-purified splenic CD11b+ monocytes from 
healthy controls (n = 4), from mice immunized only with Freund’s 
Complete Adjuvant (CFA, n = 4) and from mice with EAE—at 
onset of disease (n = 3), at peak of disease (n = 5) or treated with 
EGCG (n = 4) encompassing two to four independent EAE experi-
ments. b Quantification of mean normalized area of NOX activation 
of MACS-enriched blood CD11b+ human monocytes from age- and 
gender-matched healthy controls (n = 6), patients with clinically 
isolated syndrome (CIS, n = 5), untreated RRMS patients (n = 6), 
RRMS patients treated either with glatiramer acetate (GA) and pla-
cebo (n = 6) or with glatiramer acetate and EGCG (n = 6) as well 
as SPMS patients with their regular MS-related therapy (n = 6). a, 
b Data points are mean values of at least 50 cells from one individ-
ual, for the statistic evaluation we applied ANOVA tests (*p < 0.05, 
**p < 0.01, ***p < 0.001). c Representative color-encoded τ2 
NAD(P)H fluorescence lifetime images of MACS-enriched blood 
CD11b+ human monocytes
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enzymes in vivo (Fig. 4e). This is consistent with the find-
ings that the reactive oxidative burst is counter-regulated 
in MS by myelin-loaded macrophages up-regulating anti-
oxidant enzymes [14, 17, 58]. The toxic role of excessive 
ROS production in MS pathogenesis has been proposed 
to be related to multiple mechanisms, including enhanced 
blood–brain barrier transmigration [56], oligodendrocyte 
damage, and mitochondrial damage leading to further 
ROS production. Here, we provide evidence for an addi-
tional mechanism of NOX enzymes-mediated pathogen-
esis in MS: direct induction of neuronal dysfunction. We 
demonstrated in vivo that NOX enzymes activity leading 
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Fig. 6  NOX subunits expression levels and co-localization in human 
peripheral CD11b+ cells as well as ROS detection in serum during 
chronic neuroinflammation. a Representative images of cells, gen-
erated by imaging flow cytometry immunostained for CD11b, p22 
(membrane-bound NOX subunit) and p47 (cytosolic NOX subu-
nit). Cells shown are gated on CD11b (not shown). The upper panel 
depicts cells with high bright detail similarity (>2) between p22 
and p47 patterns (activated NOX), whereas the lower panel shows 
cells with low bright detail similarity (<1). b Less CD11b+ cells of 
a healthy control show high similarity (>2) between p22 and p47 as 
compared to an untreated RRMS patient. c The table depicts corre-
sponding cell numbers and percentages from two healthy controls and 
two untreated RRMS patients showing that CD11b+ cells with high 
similarity between p22 and p47, indicating activated NOX, are at 
least 20× more frequent in untreated RRMS patients than in healthy 
controls. d Results of DCF fluorescence-based ROS/RNS detection 
assay in serum of patients show a general trend of lower ROS/RNS 
production in glatiramer acetate (GA) treated RRMS patients after 
EGCG complementary therapy as compared to placebo. e Analyzed 
gp91 cDNA levels of PBMCs with qRT-PCR showed no difference in 
expression levels in patients pre- or post-treatment with EGCG
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to excessive ROS production was spatially correlated with 
pathologically increased neuronal calcium—a reliable indi-
cator of neuronal dysfunction at lesion sites [7, 48].
The activation of astrocytes towards oxidative stress 
generation in chronic neuroinflammation supports the 
hypothesis that these cells are partially responsible for 
the accumulated neuronal dysfunction and damage over 
the course of the disease. In the later phases of the dis-
ease, activated astrocytes and microglia may continue 
to enhance neuronal loss even in the absence of overt 
immune infiltration of the CNS. Thus, these cells may 
become a major target of therapy, especially in the pro-
gressive phase of the disease. We also employed our 
NAD(P)H-FLIM technique, under in vitro conditions, to 
monitor NOX enzymes activation in peripheral cells. The 
elevated NOX activation in monocytes from the periphery 
of EAE mice and of MS patients at various stages of the 
disease strengthens the view that both MS and EAE have a 
complex systemic dimension. Increased NOX activation in 
peripheral monocytes is not specific for MS, as we could 
also see moderately elevated NOX activation in individu-
als with common cold (data not shown). However, we saw 
a significant increase of NOX activation with disease pro-
gression, similar to our observation in the target organ, the 
CNS. The time-dependent increase in MS patients from no 
overactivation at the beginning of the disease (CIS patients 
and EAE onset) to elevated NOX activity in RRMS and 
SPMS patients’ PBMCs we observed, in conjunction with 
data from other groups showing overexpression of NOX 
subunits in the CNS tissue of progressive MS patients 
at lesion sites [13] supports the hypothesis that during 
the course of the disease the immune system (and possi-
bly also CNS components like astrocytes and microglia) 
develops an “oxidative stress memory”. Our findings are 
furthermore in accordance with data showing that in the 
chronic phase of the disease oxidized DNA, damaged 
lipids, and proteins are present in PBMCs of MS patients 
[21], supporting the proposition that excessive ROS plays 
a major role in the progressive phase of the disease.
Collectively, these results point to new treatment strate-
gies aiming to reduce oxidative stress in MS. EGCG, the 
major polyphenolic compound of the green tea plant has 
been investigated under numerous conditions. Although 
the molecular mechanisms of its actions are not fully 
understood [33], there is experimental data pointing to 
the inhibition of ROS production through EGCG in vitro 
[63]. Empirically, we showed that EGCG is neuroprotec-
tive in EAE, it is known to influence T cell and neuronal 
function [2, 19, 61] and clinical trials investigating the 
effects of EGCG (NCT00525668, NCT00799890 and 
NCT01417312) are ongoing.
In the current study, we demonstrated a direct anti-oxi-
dative mechanism of EGCG on PBMCs of MS patients. 
Oral treatment with EGCG completely counteracted the 
chronic NOX overactivation in MS patients, consistent with 
a higher enzymatic activity, as we could not detect over-
expression of NOX2 subunit gp91 by qRT-PCR. Since it 
is known that EGCG inhibits the binding of NADPH to 
enzymes within the cell, we observed the mechanism of 
blocking NADPH binding to NADPH oxidases.
Beside insights into the cellular sources of oxidative 
stress in EAE and MS, in the CNS and in the periphery, 
this work demonstrates the unique versatility of intravital 
NAD(P)H-FLIM as a marker-free method to investigate 
mechanisms of oxidative stress in inflammatory patholo-
gies, underscoring its intriguing potential for biomedicine 
as well as clinical research, in a more general context.
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